MicroRNAs as Onco-miRs, drivers of cancer.
Hede
Karyn
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D053843:DNA Mismatch Repair / Q000235:genetics*; D018450:Disease Progression; D020868:Gene Silencing; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D035683:MicroRNAs / Q000187:drug effects / Q000235:genetics; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D035683:MicroRNAs; D000068878:Trastuzumab; C524940:MIRN21 microRNA, human; C531950:MIRN21 microRNA, mouse; C528163:MIRN26 microRNA, human